{
    "body": "Idarucizumab is an antidote of which drug?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/26069913", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25899749", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26088576", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26095746", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26088268"
    ], 
    "ideal_answer": [
        "Idarucizumab is an antidote of Dabigatran. It is used for Dabigatran Reversal."
    ], 
    "exact_answer": [
        "dabigatran"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000931"
    ], 
    "type": "factoid", 
    "id": "56c079b1ef6e394741000022", 
    "snippets": [
        {
            "offsetInBeginSection": 197, 
            "offsetInEndSection": 355, 
            "text": "With Idarucizumab and Andexanet Alfa, specific antidotes have been developed against both, direct thrombin inhibitors as well as direct Factor Xa inhibitors. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26069913", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 847, 
            "offsetInEndSection": 966, 
            "text": "Three novel molecules (idarucizumab, andexanet, and PER977) may provide the most effective and safest way of reversal. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088576", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 79, 
            "text": "Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25899749", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 145, 
            "offsetInEndSection": 401, 
            "text": "We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. Dabigatran etexilate (DE) dose-dependently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idarucizumab. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25899749", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 650, 
            "offsetInEndSection": 779, 
            "text": "Thus, idarucizumab prevents excess intracerebral hematoma formation in mice anticoagulated with dabigatran and reduces mortality.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25899749", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 371, 
            "text": "BACKGROUND: Idarucizumab is a monoclonal antibody fragment that binds dabigatran with high affinity in a 1:1 molar ratio. We investigated the safety, tolerability, and efficacy of increasing doses of idarucizumab for the reversal of anticoagulant effects of dabigatran in a two-part phase 1 study (rising-dose assessment and dose-finding, proof-of-concept investigation).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088268", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 199, 
            "text": "Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088268", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 3048, 
            "offsetInEndSection": 3337, 
            "text": "INTERPRETATION: These phase 1 results show that idarucizumab was associated with immediate, complete, and sustained reversal of dabigatran-induced anticoagulation in healthy men, and was well tolerated with no unexpected or clinically relevant safety concerns, supporting further testing. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26088268", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 37, 
            "text": "Idarucizumab for Dabigatran Reversal.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095746", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 99, 
            "offsetInEndSection": 468, 
            "text": "Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.METHODS: We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of dabigatran in patients who had serious bleeding (group A) or required an urgent procedure (group B).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095746", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1835, 
            "offsetInEndSection": 1936, 
            "text": ".CONCLUSIONS: Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095746", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 145, 
            "offsetInEndSection": 260, 
            "text": "We examined the efficacy of idarucizumab, an antibody fragment binding to dabigatran, in a mouse model of OAC-ICH. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25899749", 
            "endSection": "abstract"
        }
    ]
}